Fusion Pharmaceuticals (Fusion Pharmaceuticals) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of May. 05, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Fusion Pharmaceuticals EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Fusion Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Fusion Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Fusion Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fusion Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Fusion Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

Fusion Pharmaceuticals (NAS:FUSN) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Fusion Pharmaceuticals EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Fusion Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusion Pharmaceuticals (Fusion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Pharmaceuticals Inc (NAS:FUSN) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

N/A

Address

270 Longwood Road South, Hamilton, ON, CAN, L8P 0A6

Website

https://www.fusionpharma.com

Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others.

Executives

Teresa Marie Bitetti	director	40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jeremy Bender	director	395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
David D. Meek	director	3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906
Dmitri Bobilev	officer: Chief Medical Officer	C/O FUSION PHARMACEUTICALS INC., 270 LONGWOOD RD. SOUTH, HAMILTON Z4 L8P 0A6
Steven Gannon	director	C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8
John Valliant	director, officer: Chief Executive Officer	FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON A6 L8P 0A6
Christopher P Leamon	officer: Chief Scientific Officer	C/O FUSION PHARMACEUTICALS INC., 2 INTERNATIONAL PLACE SUITE 2310, BOSTON MA 02110
Mohit Rawat	officer: President and CBO	FUSION PHARMACEUTICALS INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P 0A6
Donald A Bergstrom	director	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Philina Lee	director	C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6
Adams Street Partners Llc	10 percent owner	ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Barbara Gayle Duncan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
John J Crowley	officer: Chief Financial Officer	251 BALLARDVALE STREET, WILMINGTON MA 01887
Healthcap Vii, L.p.	10 percent owner	18 AVENUE D'OUCHY, CH 1006 LAUSANNE V8 1000-1018
James J O'leary	officer: Chief Medical Officer	830 WINTER STREET, WALTHAM MA 02452